BioCentury
ARTICLE | Clinical News

Pfizer's Xeljanz passes third Phase III test in UC

July 29, 2016 7:00 AM UTC

Pfizer Inc. (NYSE:PFE) said Xeljanz tofacitinib met the primary endpoint in the Phase III OCTAVE Sustain trial evaluating the therapy as a maintenance treatment in adults with moderately to severely active ulcerative colitis (UC). A significantly greater proportion of patients receiving Xeljanz compared to placebo were in remission at week 52, the study's primary endpoint.

OCTAVE Sustain enrolled patients who completed and achieved a clinical response in two other Phase III studies, OCTAVE Induction 1 and 2. Last September, Pfizer said Xeljanz met those studies' primary endpoints (see BioCentury Extra, Sept. 21, 2015). ...